INSMED INC (INSM) Fundamental Analysis & Valuation

NASDAQ:INSM • US4576693075

Current stock price

143.93 USD
-0.67 (-0.46%)
At close:
143.93 USD
0 (0%)
After Hours:

This INSM fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. INSM Profitability Analysis

1.1 Basic Checks

  • INSM had negative earnings in the past year.
  • INSM had a negative operating cash flow in the past year.
  • INSM had negative earnings in each of the past 5 years.
  • INSM had a negative operating cash flow in each of the past 5 years.
INSM Yearly Net Income VS EBIT VS OCF VS FCFINSM Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 -200M -400M -600M -800M -1B

1.2 Ratios

  • INSM has a Return On Assets (-56.38%) which is comparable to the rest of the industry.
  • INSM has a Return On Equity of -172.78%. This is in the lower half of the industry: INSM underperforms 66.41% of its industry peers.
Industry RankSector Rank
ROA -56.38%
ROE -172.78%
ROIC N/A
ROA(3y)-52.62%
ROA(5y)-44.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
INSM Yearly ROA, ROE, ROICINSM Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200 -200 -400

1.3 Margins

  • INSM has a Gross Margin of 79.73%. This is amongst the best in the industry. INSM outperforms 84.75% of its industry peers.
  • INSM's Gross Margin has been stable in the last couple of years.
  • The Profit Margin and Operating Margin are not available for INSM so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 79.73%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y1.03%
INSM Yearly Profit, Operating, Gross MarginsINSM Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. INSM Health Analysis

2.1 Basic Checks

  • INSM does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • INSM has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for INSM has been increased compared to 5 years ago.
  • INSM has a better debt/assets ratio than last year.
INSM Yearly Shares OutstandingINSM Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M 200M
INSM Yearly Total Debt VS Total AssetsINSM Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B 2B

2.2 Solvency

  • INSM has an Altman-Z score of 8.29. This indicates that INSM is financially healthy and has little risk of bankruptcy at the moment.
  • The Altman-Z score of INSM (8.29) is better than 80.12% of its industry peers.
  • A Debt/Equity ratio of 0.98 indicates that INSM is somewhat dependend on debt financing.
  • The Debt to Equity ratio of INSM (0.98) is worse than 75.48% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF N/A
Altman-Z 8.29
ROIC/WACCN/A
WACC8.78%
INSM Yearly LT Debt VS Equity VS FCFINSM Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 500M -500M 1B

2.3 Liquidity

  • INSM has a Current Ratio of 3.83. This indicates that INSM is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of INSM (3.83) is comparable to the rest of the industry.
  • A Quick Ratio of 3.54 indicates that INSM has no problem at all paying its short term obligations.
  • With a Quick ratio value of 3.54, INSM perfoms like the industry average, outperforming 43.63% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 3.83
Quick Ratio 3.54
INSM Yearly Current Assets VS Current LiabilitesINSM Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. INSM Growth Analysis

3.1 Past

  • INSM shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -14.67%.
  • Looking at the last year, INSM shows a very strong growth in Revenue. The Revenue has grown by 66.73%.
  • The Revenue has been growing by 29.83% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)-14.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
Revenue 1Y (TTM)66.73%
Revenue growth 3Y35.2%
Revenue growth 5Y29.83%
Sales Q2Q%152.62%

3.2 Future

  • INSM is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 29.72% yearly.
  • INSM is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 66.02% yearly.
EPS Next Y54.28%
EPS Next 2Y44.06%
EPS Next 3Y37.98%
EPS Next 5Y29.72%
Revenue Next Year210.82%
Revenue Next 2Y127.13%
Revenue Next 3Y95.62%
Revenue Next 5Y66.02%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
INSM Yearly Revenue VS EstimatesINSM Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2016 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 2B 4B 6B 8B 10B
INSM Yearly EPS VS EstimatesINSM Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 0 5 -5 10 15 20

More info and screens

Find the best growth stocksShow best growing peers

1

4. INSM Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for INSM. In the last year negative earnings were reported.
  • Also next year INSM is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
INSM Price Earnings VS Forward Price EarningsINSM Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 -40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
INSM Per share dataINSM EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as INSM's earnings are expected to grow with 37.98% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y44.06%
EPS Next 3Y37.98%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. INSM Dividend Analysis

5.1 Amount

  • INSM does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

INSM Fundamentals: All Metrics, Ratios and Statistics

INSMED INC

NASDAQ:INSM (3/17/2026, 4:10:09 PM)

After market: 143.93 0 (0%)

143.93

-0.67 (-0.46%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)01-09
Earnings (Next)05-06
Inst Owners101.55%
Inst Owner Change-1.17%
Ins Owners0.54%
Ins Owner Change-10.31%
Market Cap31.02B
Revenue(TTM)606.42M
Net Income(TTM)-1.28B
Analysts85.38
Price Target216.28 (50.27%)
Short Float %5.28%
Short Ratio4.62
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-22.54%
Min EPS beat(2)-28.09%
Max EPS beat(2)-16.99%
EPS beat(4)0
Avg EPS beat(4)-19.6%
Min EPS beat(4)-28.87%
Max EPS beat(4)-4.46%
EPS beat(8)1
Avg EPS beat(8)-15.82%
EPS beat(12)2
Avg EPS beat(12)-15.8%
EPS beat(16)4
Avg EPS beat(16)-12.57%
Revenue beat(2)2
Avg Revenue beat(2)35.81%
Min Revenue beat(2)20.71%
Max Revenue beat(2)50.91%
Revenue beat(4)3
Avg Revenue beat(4)17.97%
Min Revenue beat(4)-1.17%
Max Revenue beat(4)50.91%
Revenue beat(8)4
Avg Revenue beat(8)8.23%
Revenue beat(12)5
Avg Revenue beat(12)5.82%
Revenue beat(16)6
Avg Revenue beat(16)4.28%
PT rev (1m)-1.33%
PT rev (3m)-0.48%
EPS NQ rev (1m)2.97%
EPS NQ rev (3m)21.11%
EPS NY rev (1m)4.12%
EPS NY rev (3m)21.45%
Revenue NQ rev (1m)20.52%
Revenue NQ rev (3m)58.75%
Revenue NY rev (1m)17.63%
Revenue NY rev (3m)37.04%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 51.16
P/FCF N/A
P/OCF N/A
P/B 41.98
P/tB 61.41
EV/EBITDA N/A
EPS(TTM)-6.41
EYN/A
EPS(NY)-2.93
Fwd EYN/A
FCF(TTM)-4.49
FCFYN/A
OCF(TTM)-4.34
OCFYN/A
SpS2.81
BVpS3.43
TBVpS2.34
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -56.38%
ROE -172.78%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 79.73%
FCFM N/A
ROA(3y)-52.62%
ROA(5y)-44.38%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.95%
GM growth 5Y1.03%
F-Score4
Asset Turnover0.27
Health
Industry RankSector Rank
Debt/Equity 0.98
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 169.93%
Cap/Sales 5.37%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.83
Quick Ratio 3.54
Altman-Z 8.29
F-Score4
WACC8.78%
ROIC/WACCN/A
Cap/Depr(3y)143.21%
Cap/Depr(5y)111.56%
Cap/Sales(3y)5.25%
Cap/Sales(5y)4.73%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-14.67%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-16.67%
EPS Next Y54.28%
EPS Next 2Y44.06%
EPS Next 3Y37.98%
EPS Next 5Y29.72%
Revenue 1Y (TTM)66.73%
Revenue growth 3Y35.2%
Revenue growth 5Y29.83%
Sales Q2Q%152.62%
Revenue Next Year210.82%
Revenue Next 2Y127.13%
Revenue Next 3Y95.62%
Revenue Next 5Y66.02%
EBIT growth 1Y-26.47%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year43.95%
EBIT Next 3Y38.19%
EBIT Next 5YN/A
FCF growth 1Y-37.09%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-36.72%
OCF growth 3YN/A
OCF growth 5YN/A

INSMED INC / INSM Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for INSMED INC?

ChartMill assigns a fundamental rating of 3 / 10 to INSM.


Can you provide the valuation status for INSMED INC?

ChartMill assigns a valuation rating of 1 / 10 to INSMED INC (INSM). This can be considered as Overvalued.


How profitable is INSMED INC (INSM) stock?

INSMED INC (INSM) has a profitability rating of 1 / 10.


What is the financial health of INSMED INC (INSM) stock?

The financial health rating of INSMED INC (INSM) is 4 / 10.